Andrew A. Hindman is Chief Business Officer at ACORDA THERAPEUTICS INC (ACOR). They have made 4 open-market trades across 2 companies since 2015, most recently 2022-11-20.
CIK 0001607965
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TBPH | SELL | 2022-11-18 | 2022-11-22 | $11.02 | $716K | +5.6% | +10.0% | -1.4% |
| ACOR | SELL · 10b5-1 | 2018-12-03 | 2018-12-06 | $20.56 | $15K | -15.8% | -12.6% | -26.9% |
| ACOR | SELL | 2018-05-25 | 2018-05-30 | $24.26 | $2.1M | +24.4% | +9.5% | +10.3% |
| ACOR | SELL · 10b5-1 | 2017-12-01 | 2017-12-05 | $20.54 | $17K | +3.2% | +3.2% | +27.2% |
| ACOR | SELL | 2017-05-15 | 2017-05-17 | $15.75 | $121K | -6.0% | +15.0% | +41.3% |
| ACOR | SELL · 10b5-1 | 2016-12-01 | 2016-12-05 | $20.72 | $9K | +0.7% | -3.5% | +27.8% |
| ACOR | SELL | 2016-05-13 | 2016-05-16 | $26.11 | $254K | +0.2% | -2.5% | -9.6% |
| ACOR | SELL · 10b5-1 | 2015-12-01 | 2015-12-03 | $38.26 | $17K | -8.7% | +0.7% | -15.3% |
| ACOR | SELL · 10b5-1 | 2015-05-13 | 2015-05-15 | $29.82 | $142K | -8.7% | +0.7% | +0.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.